Cel Sci (CVM) Share-based Compensation Growth (5y) (2015 - 2026)
Cel Sci (CVM) Share-based Compensation Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.75% |
| Dec 31, 2025 | 12.26% |
| Sep 30, 2025 | 34.25% |
| Jun 30, 2025 | -52.72% |
| Mar 31, 2025 | 29.06% |
| Dec 31, 2024 | -16.95% |
| Sep 30, 2024 | -53.66% |
| Jun 30, 2024 | 32.75% |
| Mar 31, 2024 | 21.96% |
| Dec 31, 2023 | 19.26% |
| Sep 30, 2023 | 60.26% |
| Jun 30, 2023 | 111.48% |
| Mar 31, 2023 | 116.65% |
| Dec 31, 2022 | 116.43% |
| Sep 30, 2022 | 14.59% |
| Jun 30, 2022 | 49.74% |
| Mar 31, 2022 | 56.16% |
| Dec 31, 2021 | 110.70% |
| Sep 30, 2021 | 19.19% |
| Jun 30, 2021 | 53.02% |